GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

ivarmacitinib   Click here for help

GtoPdb Ligand ID: 11878

Synonyms: example 34 [WO2013091539A1] [7] | SHR-0302 | SHR0302
Approved drug Immunopharmacology Ligand
ivarmacitinib is an approved drug
Compound class: Synthetic organic
Comment: Ivarmacitinib (SHR0302) is an oral Janus kinase (JAK) inhibitor, with selectivity for JAK1. It is being investigated for anti-inflammatory potential in auto-inflammatory diseases [5-6,9]. Likely to be administered as the bisulfate salt as outlined in patent WO2014194741A1 [4].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

ivarmacitinib is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 140.4
Molecular weight 414.16
XLogP 1.7
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES COc1nsc(n1)NC(=O)N1C[C@@H]2[C@H](C1)CC(C2)N(c1ncnc2c1cc[nH]2)C
Isomeric SMILES CN(C1C[C@@H]2CN(C[C@@H]2C1)C(=O)Nc1nc(ns1)OC)c1ncnc2c1cc[nH]2
InChI InChI=1S/C18H22N8O2S/c1-25(15-13-3-4-19-14(13)20-9-21-15)12-5-10-7-26(8-11(10)6-12)18(27)23-17-22-16(28-2)24-29-17/h3-4,9-12H,5-8H2,1-2H3,(H,19,20,21)(H,22,23,24,27)/t10-,11+,12?
InChI Key DNBCBAXDWNDRNO-FOSCPWQOSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Ivarmacitinib (SHR0302) was advanced to clinical evaluation in a range of auto-inflammatory conditions. First approval was granted in China in 2024. Under this authorisation ivarmacitinib can be prescribed to treat rheumatoid arthritis, atopic dermatitis and active ankylosing spondylitis. Ivarmacitinib is also being evaluated for potential to reverse acquired resistance to immunotherapies in cancer patients.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04162899 A Phase II Study in Adult Patients With Moderate to Severe Atopic Dermatitis Phase 2 Interventional Reistone Biopharma Company Limited 9
NCT05181137 A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis Phase 3 Interventional Reistone Biopharma Company Limited
NCT04346316 A Phase II Study in Patients With Alopecia Areata Phase 2 Interventional Reistone Biopharma Company Limited
NCT04333771 A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis Phase 3 Interventional Jiangsu HengRui Medicine Co., Ltd. 2
NCT04875169 Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis Phase 3 Interventional Reistone Biopharma Company Limited 8
NCT06731153 JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC Phase 2 Interventional Fudan University 8
NCT03675477 A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis. Phase 2 Interventional Reistone Biopharma Company Limited 1
NCT04481139 A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Ankylosing Spondylitis Phase 2/Phase 3 Interventional Jiangsu HengRui Medicine Co., Ltd. 3